Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson’s disease symptoms by regulating brain amyloid β1–42 level

Cerebrospinal fluid Aβ42levels andAPPprocessing pathway genes in Parkinson's disease

(2015) Lynn M. Bekris et al.   MOVEMENT DISORDERS

Repetitive transcranial magnetic stimulation of the primary motor cortex in the treatment of motor signs in Parkinson's disease: A quantitative review of the literature

(2015) Anosha Zanjani et al.   MOVEMENT DISORDERS

Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases

(2015) Zhen Ni et al.   Translational Neurodegeneration

Low-frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) reverses Aβ1–42-mediated memory deficits in rats

(2013) Tao Tan et al.   EXPERIMENTAL GERONTOLOGY

Cerebrospinal fluid biomarkers in Parkinson disease

(2013) Lucilla Parnetti et al.   Nature Reviews Neurology

Clinical use of cerebrospinal fluid biomarkers in Alzheimer’s disease

(2012) Henrik Zetterberg et al.   Biomarkers in Medicine

Parkinson's disease subtypes: lost in translation?

(2012) C. Marras et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Nigral pathology and parkinsonian signs in elders without Parkinson disease

(2011) Aron S. Buchman et al.   ANNALS OF NEUROLOGY

Long-Term Effects of Repetitive Transcranial Magnetic Stimulation on Markers for Neuroplasticity: Differential Outcomes in Anesthetized and Awake Animals

(2011) R. Gersner et al.   JOURNAL OF NEUROSCIENCE

Repetitive Transcranial Magnetic Stimulation Enhances BDNF-TrkB Signaling in Both Brain and Lymphocyte

(2011) H.-Y. Wang et al.   JOURNAL OF NEUROSCIENCE

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

(2011) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Problems associated with fluid biomarkers for Parkinson’s disease

(2010) Jakob Nyhlén et al.   Biomarkers in Medicine

Soluble βamyloid1-42: a critical player in producing behavioural and biochemical changes evoking depressive-related state?

(2010) M Colaianna et al.   BRITISH JOURNAL OF PHARMACOLOGY

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach

(2010) Karin D. van Dijk et al.   NEUROBIOLOGY OF DISEASE

Incidence and remaining lifetime risk of Parkinson disease in advanced age

(2009) J. A. Driver et al.   NEUROLOGY

S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10

(2009) Weiping Qin et al.   PLoS One

Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease

(2008) Henrik Zetterberg et al.   ARCHIVES OF NEUROLOGY

Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

(2008) Michael Ewers et al.   BRAIN

Decrease in age-adjusted cerebrospinal fluid β-secretase activity in Alzheimer's subjects

(2008) Guoxin Wu et al.   CLINICAL BIOCHEMISTRY

A Closer Look at α-Secretase

(2008) Rolf Postina   Current Alzheimer Research

Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17

(2008) Miriam Deuss et al.   Current Alzheimer Research

Effect of transcranial magnetic stimulation on Parkinson motor function-Systematic review of controlled clinical trials

(2008) Behzad Elahi et al.   MOVEMENT DISORDERS